Showing 421 - 440 results of 743 for search '"Bristol Myers Squibb"', query time: 0.15s Refine Results
  1. 421
  2. 422
  3. 423
  4. 424
  5. 425
  6. 426
  7. 427
  8. 428

    Modern Antiplatelet Therapy: When Is Clopidogrel the Right Choice? by Kendrick Shunk, Punag Divanji

    Published 2018-06-01
    “…In the era of percutaneous coronary intervention with drug-eluting stents, dual anti-platelet therapy with the addition of clopidogrel (Plavix©, Bristol-Myers Squibb, New York, NY) became the mainstay of therapy. …”
    Get full text
    Article
  9. 429

    Intravenous paracetamol and intraocular pressure reduction: mannitol may also be involved by Allegaert K

    Published 2016-09-01
    “…Karel Allegaert1,2 1Intensive Care, Department of Surgery, Erasmus MC Sophia Children’s Hospital, Rotterdam, the Netherlands; 2Department of Development and Regeneration, KU Leuven, BelgiumI read, with great interest, the paper on the intraocular pressure-lowering properties of intravenous paracetamol (acetaminophen) recently published in this journal by van den Heever and Meyer.1 The authors documented a decrease from baseline in mean intraocular pressure of 15.7% in a 6-hour time interval following intravenous paracetamol (1 g Perfalgan®, Bristol-Myers Squibb, New York, NY, USA) administration. …”
    Get full text
    Article
  10. 430
  11. 431
  12. 432
  13. 433

    News at Six: Hepatitis C Special by Mark Thursz, Jean-Michel Pawlotsky, Heiner Wedemeyer, Ashley Brown, Charles Gore, Alessandra Mangia, Graham Foster, Rafael Esteban

    Published 2014-05-01
    “…This Bristol Myers Squibb-sponsored symposium was chaired by Mark Thursz, who oversaw a novel news bulletin-themed symposium with sessions provided by a distinguished, international team of roving reporters; Charles Gore from the World Hepatitis Alliance, Jean-Michel Pawlotsky from France, Alessandra Mangia from Italy, Ashley Brown and Graham Foster from London, Heiner Wedemeyer from Germany, and Rafael Esteban from Spain.…”
    Get full text
    Article
  14. 434
  15. 435
  16. 436
  17. 437
  18. 438

    Ipilimumab: A novel immunomodulating therapy causing autoimmune hypophysitis: A case report and review by Juszczak, A, Gupta, A, Karavitaki, N, Middleton, MR, Grossman, AB

    Published 2012
    “…Ipilimumab (Yervoy; Medarex and Bristol-Myers Squibb) is a human MAB against cytotoxic T-lymphocyte antigen 4, which enhances co-stimulation of cytotoxic T-lymphocytes, resulting in their proliferation and an anti-tumour response. …”
    Journal article
  19. 439
  20. 440